The story so far:

Now Sacco will do the same for Optibiotix’s patented product in the USA and the Rest of the World in return for 50 per cent of the profit.

As well as giving access to the world’s largest probiotic market in the US, the new agreement assists and extension of LPLDL into diary products utilising Sacco’s network in the dairy industry to develop commercial opportunities.

Stephen O’Hara comments: “This new agreement with Sacco significantly extends the scale of the commercial opportunity open to LPLDL to new application areas and territories, and reflects growing confidence from both companies in LPLDL’s market potential.”

Optibiotix Health announced yesterday it plans for a US launch of LPLDL, its cholesterol and blood pressure lowering product, at Supply Side West in Las Vegas, on September 27 and 28. OptiBiotix will co-exhibit with Sacco.

For the full story please see the York Press website.

"We chose Sacco as we have been impressed by their ability to introduce LPLDL to a global network of distributors and believe extending our partnership with them provides the best opportunity of quickly building revenues and developing LPLDL into a global brand. In addition, the ability to supply competitively priced ingredients from a single manufacturer across world markets simplifies the supply chain and contract negotiations with corporate partners." Stephen O’Hara - Chief Executive